Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06285643

A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

Recruiting

Interested in participating?

Request Info

Key information

Age range

45 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Charité - Universitätsmedizin Berlin (Surgical), Berlin, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age

  • Male and female adults 45-75 years of age inclusive, at the time of signing of informed consent Type of Subject and Disease Characteristics
  • Diagnosed with Parkinson's disease in the past 4-10 years (inclusive) as defined by the following:
  • Presence of bradykinesia PLUS any of the following:
  • Rigidity
  • Rest tremor
  • Postural instability
  • Presence of motor fluctuations as measured by the PD Motor Diary
  • Stable anti-parkinsonian medication regimen for >/= 4 weeks prior to screening
  • Must demonstrate responsiveness to levodopa therapy

Exclusion criteria

  • Known history or current evidence of medical, genetic, or neurological conditions that may provide an alternative to idiopathic PD diagnosis
  • Presence or history of significant vascular and/or cardiovascular disease
  • Presence of significant cognitive impairment, poorly controlled depression/anxiety
  • Presence or history of psychosis or impulse control disorder
  • History of malignancy other than treated cutaneous squamous or basal cell carcinomas
  • Presence of clinically relevant conditions that could compromise surgical suitability and/or subject safety
  • Contraindication to magnetic resonance imaging and/or use gadolinium-based contrast agents
  • Prior history of brain surgery including, but no limited: DBS, pallidotomy focused ultrasound thalamotomy, or other experimental neurosurgical procedure
  • Chronic immunosuppressive therapy

Treatment and study plan

AAV2-GDNF gene therapy

Drug

Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose

Other names: Biological

control surgery

Procedure

Bilateral partial burr/twist holes without dural penetration

Primary outcomes

  1. Change from baseline to Month 18 on PD Motor Diary

    Time frame: 18 months

    Normalized Good ON time per Hauser Diary

Study contacts

Contact information is provided by the study sponsor or research team.

Gayathri Palety, MD

CONTACT

[email protected]

919-388-1040

Nisha Chhabria, MD

CONTACT

[email protected]

919-388-1040

Sponsors and collaborators

Lead sponsor

AskBio Inc

Industry

Collaborators

  • Bayer

Registry information

Official study title

A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease

Acronym: REGENERATE-PD

Important dates

Study start
2024
Primary completion
2028
Study completion
2028
First posted
Feb 29, 2024
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.